HSIC
Henry Schein, Inc.
HSIC has lower modeled downside risk, despite its lower overall score.
LLY
Eli Lilly and Company
LLY has the edge over HSIC overall, supported by stronger fundamentals and stronger valuation.
HSIC Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Under pressure |
HSIC's profitability and cash flow are currently healthy, and its revenue is stable, but its balance sheet is under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
HSIC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 15x | $86.14 | — |
| Cheap | 17x | $60.99 | -29% |
| Fair | 21x | $78.46 | -8.9% |
| Current | 24x | $86.14 | — |
| Expensive | 25x | $90.36 | +4.9% |
Historical ranges are pointers, not guarantees.
HSIC has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
HSIC Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for HSIC, with profitability holding steady.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over HSIC on the outlook, with more favorable profitability expectations.
HSIC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.82 | +59% |
| Q3 2026 | $3.65 | +15% |
| Q2 2026 | $3.43 | +10% |
| Q1 2026 | $3.31 | +3.1% |
| Q4 2025 | $3.27 | +7.2% |
| Q3 2025 | $3.17 | +30% |
| Q2 2025 | $3.11 | +15% |
| Q1 2025 | $3.21 | +8.1% |
| Q4 2024 | $3.05 | -3.5% |
HSIC's earnings per share have fallen from their peak: $3.65 over the past year, against $4.88 in early 2020.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over HSIC on earnings, with more consistent year-over-year improvement.
HSIC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3.5B | +4% |
| Q2 2026 | $3.5B | +6.7% |
| Q1 2026 | $3.4B | +6.3% |
| Q4 2025 | $3.4B | +7.7% |
| Q3 2025 | $3.3B | +5.2% |
| Q2 2025 | $3.2B | +3.3% |
| Q1 2025 | $3.2B | -0.1% |
| Q4 2024 | $3.2B | +5.8% |
HSIC's revenue has grown year over year for six quarters in a row: $3.5B last quarter, up 4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.6% | +0.6 points |
| Q2 2026 | 5% | +0.3 points |
| Q1 2026 | 5.4% | -0.1 points |
| Q4 2025 | 4.7% | -0.1 points |
| Q3 2025 | 4.9% | 0 points |
| Q2 2025 | 4.7% | -0.4 points |
| Q1 2025 | 5.5% | +0.8 points |
| Q4 2024 | 4.9% | +3.6 points |
HSIC's operating margin was 5.6% last quarter, up 0.6 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over HSIC on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over HSIC on profitability, with a higher operating margin.
HSIC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $131M | -7.1% |
| Q2 2026 | $212M | +141% |
| Q1 2026 | -$122M | -2133% |
| Q4 2025 | $338M | +101% |
| Q3 2025 | $141M | +21% |
| Q2 2025 | $88M | -66% |
| Q1 2025 | $6M | -96% |
| Q4 2024 | $168M | +$239M |
HSIC generated $559M in free cash flow over the past year, up 39% from the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over HSIC on cash flow, with more consistent year-over-year improvement.
HSIC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.6% | -1.9M shares |
| 1 year | -7% | -8.5M shares |
| 3 years | -14% | -18.9M shares |
| 5 years | -20% | -28.5M shares |
| Available history | -25% | -36.7M shares |
HSIC has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $125M |
| Q2 2026 | $200M |
| Q1 2026 | $125M |
| Q4 2025 | $200M |
| Q3 2025 | $203M |
| Q2 2025 | $286M |
| Q1 2025 | $161M |
| Q4 2024 | $75M |
HSIC spent $650M buying back its own shares over the past year, down 10% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
HSIC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.2x | Elevated |
| Q2 2026 | 3.3x | Elevated |
| Q1 2026 | 3.4x | Elevated |
| Q4 2025 | 3.1x | Elevated |
| Q3 2025 | 3.2x | Elevated |
| Q2 2025 | 3.1x | Elevated |
| Q1 2025 | 3.0x | Elevated |
| Q4 2024 | 2.7x | Moderate |
HSIC's net debt is about 3.2 years of its operating earnings (EBITDA), about the same as a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over HSIC on leverage, with a lower net debt burden relative to earnings.
HSIC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 55.0 | Neutral |
| Stochastic | 50.0 | Neutral |
HSIC's weekly RSI is 55 (neutral) and its Stochastic is 50 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
HSIC PE vs Healthcare Sector
| Metric | HSIC | Sector median | Relative |
|---|---|---|---|
| PE | 24x | 26x | 8.7% below |
| PE % | 73 | 29 | 44 pts above |
HSIC has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
HSIC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $85.5 | 0.8% above |
| 20 week MA | $86.6 | 0.6% below |
| 50 week MA | $80.8 | 6.7% above |
| 100 week MA | $75.4 | 14% above |
| 200 week MA | $74.8 | 15% above |
HSIC's trend is mixed: it's above four of its five weekly moving averages, and 15% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over HSIC on trend strength, trading above more of its moving averages.
HSIC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $66.6 | $65.8 | -1.1% |
| 2021 | $65.8 | $74.9 | +14% |
| 2022 | $74.9 | $80.6 | +7.6% |
| 2023 | $80.6 | $75.7 | -6.1% |
| 2024 | $75.7 | $70.4 | -7% |
| 2025 | $70.4 | $76.1 | +8.1% |
| 2026 YTD | $76.1 | $86.1 | +13% |
HSIC has finished lower in three of the last six years. It's up 13% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over HSIC on returns for 2026, with the stronger performance.